Please login to the form below

Not currently logged in
Email:
Password:

Cardax adds big pharma experience to board

Brings in former Novartis, BMS and Boehringer executives

tamar howson cardaxHawaii-based anti-inflammatory specialist Cardax has added three new members to its board, each with experience at a major pharma company.

George Bickerstaff is a former chief financial officer of Novartis who is now managing director at investment bank MM Dillon. He was also chief financial officer at IMS Health.

Tamar Howson (pictured right) is a former senior business development executive at Bristol-Myers Squibb and SmithKline Beecham (now GSK) who now acts as an independent consultant to life sciences companies.

The final new addition is Terence Kelly who provides Cardax with scientific experience having served as VP, department of medicinal chemistry at Boehringer Ingelheim. He is currently president and CEO of CoMentis, a private biotech company focused on neurodegenerative diseases.

“The distinctive, yet complementary skills of our new board members provide a strong foundation as we develop and commercialise our nutraceutical and pharmaceutical programmes,” said David Watumull, president and CEO of Cardax.

These programmes are focused on developing products that are as effective as steroids and NSAIDS but have safer profiles.

19th June 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...